FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4232199544> ?p ?o ?g. }

• W4232199544 endingPage "20088" @default.
• W4232199544 startingPage "20075" @default.
• W4232199544 abstract "// Patrick Casara 1, * , James Davidson 2, * , Audrey Claperon 3, * , Gaëtane Le Toumelin-Braizat 3 , Meike Vogler 4 , Alain Bruno 5 , Maïa Chanrion 3 , Gaëlle Lysiak-Auvity 3 , Thierry Le Diguarher 1 , Jérôme-Benoît Starck 1 , Ijen Chen 2 , Neil Whitehead 2 , Christopher Graham 2 , Natalia Matassova 2 , Pawel Dokurno 2 , Christopher Pedder 2 , Youzhen Wang 6 , Shumei Qiu 6 , Anne-Marie Girard 3 , Emilie Schneider 3 , Fabienne Gravé 3 , Aurélie Studeny 3 , Ghislaine Guasconi 3 , Francesca Rocchetti 3 , Sophie Maïga 7 , Jean-Michel Henlin 1 , Frédéric Colland 3 , Laurence Kraus-Berthier 5 , Steven Le Gouill 7 , Martin J.S. Dyer 8 , Roderick Hubbard 2 , Mike Wood 2 , Martine Amiot 7 , Gerald M Cohen 9 , John A. Hickman 3 , Erick Morris 6 , James Murray 2 and Olivier Geneste 3 1 Institut de Recherches Servier Discovery Chemistry Unit, Croissy Sur Seine, France 2 Vernalis (R&D) Ltd., Cambridge, UK 3 Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France 4 Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Frankfurt, Germany 5 Institut de Recherches Internationales Servier, Oncology R&D Unit, Suresnes, France 6 Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA, USA 7 CRCINA, INSERM, CNRS, Université de Nantes, CHU de Nantes, Nantes, France 8 Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, UK 9 Institute of Translational Medicine, University of Liverpool, Liverpool, UK * These authors contributed equally to this work Correspondence to: Olivier Geneste, email: olivier.geneste@servier.com Keywords: BCL-2; inhibitor; BH3-mimetics; apoptosis; hematological malignancies Received: September 12, 2017      Accepted: February 26, 2018      Published: April 13, 2018 ABSTRACT Escape from apoptosis is one of the major hallmarks of cancer cells. The B-cell Lymphoma 2 (BCL-2) gene family encodes pro-apoptotic and anti-apoptotic proteins that are key regulators of the apoptotic process. Overexpression of the pro-survival member BCL-2 is a well-established mechanism contributing to oncogenesis and chemoresistance in several cancers, including lymphoma and leukemia. Thus, BCL-2 has become an attractive target for therapeutic strategy in cancer, as demonstrated by the recent approval of ABT-199 (Venclexta™) in relapsed or refractory Chronic Lymphocytic Leukemia with 17p deletion. Here, we describe a novel orally bioavailable BCL-2 selective and potent inhibitor called S55746 (also known as BCL201). S55746 occupies the hydrophobic groove of BCL-2. Its selectivity profile demonstrates no significant binding to MCL-1, BFL-1 (BCL2A1/A1) and poor affinity for BCL-XL. Accordingly, S55746 has no cytotoxic activity on BCL-XL-dependent cells, such as platelets. In a panel of hematological cell lines, S55746 induces hallmarks of apoptosis including externalization of phosphatidylserine, caspase-3 activation and PARP cleavage. Ex vivo , S55746 induces apoptosis in the low nanomolar range in primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma patient samples. Finally, S55746 administered by oral route daily in mice demonstrated robust anti-tumor efficacy in two hematological xenograft models with no weight lost and no change in behavior. Taken together, these data demonstrate that S55746 is a novel, well-tolerated BH3-mimetic targeting selectively and potently the BCL-2 protein." @default.
• W4232199544 created "2022-05-12" @default.
• W4232199544 creator A5000222588 @default.
• W4232199544 creator A5002797759 @default.
• W4232199544 creator A5003041443 @default.
• W4232199544 creator A5003494614 @default.
• W4232199544 creator A5005231854 @default.
• W4232199544 creator A5006047218 @default.
• W4232199544 creator A5010727651 @default.
• W4232199544 creator A5010914815 @default.
• W4232199544 creator A5013128561 @default.
• W4232199544 creator A5018870395 @default.
• W4232199544 creator A5019757608 @default.
• W4232199544 creator A5020512155 @default.
• W4232199544 creator A5025363975 @default.
• W4232199544 creator A5025506523 @default.
• W4232199544 creator A5028007206 @default.
• W4232199544 creator A5039798176 @default.
• W4232199544 creator A5050667416 @default.
• W4232199544 creator A5050805316 @default.
• W4232199544 creator A5051136232 @default.
• W4232199544 creator A5054854094 @default.
• W4232199544 creator A5054906244 @default.
• W4232199544 creator A5056934366 @default.
• W4232199544 creator A5057221466 @default.
• W4232199544 creator A5057791233 @default.
• W4232199544 creator A5058267528 @default.
• W4232199544 creator A5063661309 @default.
• W4232199544 creator A5068144072 @default.
• W4232199544 creator A5072179479 @default.
• W4232199544 creator A5073857602 @default.
• W4232199544 creator A5074334005 @default.
• W4232199544 creator A5079274761 @default.
• W4232199544 creator A5081516283 @default.
• W4232199544 creator A5082394591 @default.
• W4232199544 creator A5085528317 @default.
• W4232199544 creator A5087427159 @default.
• W4232199544 creator A5087984939 @default.
• W4232199544 creator A5089105221 @default.
• W4232199544 creator A5091046580 @default.
• W4232199544 date "2018-04-13" @default.
• W4232199544 modified "2023-10-18" @default.
• W4232199544 title "S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth" @default.
• W4232199544 cites W1967194777 @default.
• W4232199544 cites W1977258127 @default.
• W4232199544 cites W1977873175 @default.
• W4232199544 cites W1985563073 @default.
• W4232199544 cites W1991213319 @default.
• W4232199544 cites W2019452934 @default.
• W4232199544 cites W2026450884 @default.
• W4232199544 cites W2038067635 @default.
• W4232199544 cites W2039640090 @default.
• W4232199544 cites W2043398720 @default.
• W4232199544 cites W2053805019 @default.
• W4232199544 cites W2059416155 @default.
• W4232199544 cites W2059500638 @default.
• W4232199544 cites W2082030057 @default.
• W4232199544 cites W2083113305 @default.
• W4232199544 cites W2085419794 @default.
• W4232199544 cites W2088883749 @default.
• W4232199544 cites W2089298737 @default.
• W4232199544 cites W2095453782 @default.
• W4232199544 cites W2097290512 @default.
• W4232199544 cites W2103980474 @default.
• W4232199544 cites W2110525250 @default.
• W4232199544 cites W2111163870 @default.
• W4232199544 cites W2113278680 @default.
• W4232199544 cites W2117692326 @default.
• W4232199544 cites W2133323723 @default.
• W4232199544 cites W2142713529 @default.
• W4232199544 cites W2144881954 @default.
• W4232199544 cites W2150680216 @default.
• W4232199544 cites W2168632005 @default.
• W4232199544 cites W2172242534 @default.
• W4232199544 cites W2252711380 @default.
• W4232199544 cites W2270517900 @default.
• W4232199544 cites W2329205123 @default.
• W4232199544 cites W2369297677 @default.
• W4232199544 cites W2414615618 @default.
• W4232199544 cites W2534349779 @default.
• W4232199544 cites W2589060305 @default.
• W4232199544 cites W2620804057 @default.
• W4232199544 doi "https://doi.org/10.18632/oncotarget.24744" @default.
• W4232199544 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29732004" @default.
• W4232199544 hasPublicationYear "2018" @default.
• W4232199544 type Work @default.
• W4232199544 citedByCount "70" @default.
• W4232199544 countsByYear W42321995442018 @default.
• W4232199544 countsByYear W42321995442019 @default.
• W4232199544 countsByYear W42321995442020 @default.
• W4232199544 countsByYear W42321995442021 @default.
• W4232199544 countsByYear W42321995442022 @default.
• W4232199544 countsByYear W42321995442023 @default.
• W4232199544 crossrefType "journal-article" @default.
• W4232199544 hasAuthorship W4232199544A5000222588 @default.
• W4232199544 hasAuthorship W4232199544A5002797759 @default.
• W4232199544 hasAuthorship W4232199544A5003041443 @default.
• W4232199544 hasAuthorship W4232199544A5003494614 @default.

• next